10-Q: Actuate Therapeutics Reports Third Quarter 2024 Financial Results Following Successful IPO

Actuate Therapeutics reports its third quarter 2024 financial results, highlighting its transition to a public company following a successful IPO and continued clinical development of elraglusib.

Summary

• Actuate Therapeutics, a clinical-stage biopharmaceutical company, released its financial results for the third quarter of 2024.
• The company completed its initial public offering (IPO) on August 14, 2024, raising approximately $22 million in net proceeds.
• The IPO resulted in the conversion of redeemable convertible preferred stock and related party convertible notes into common stock.
• Actuate Therapeutics reported a net loss of $5.97 million for the three months ended September 30, 2024, and a net loss of $20.84 million for the nine months ended September 30, 2024.
• Research and development expenses were $3.76 million for the quarter and $14.99 million for the nine-month period.
• General and administrative expenses were $1.64 million for the quarter and $3.61 million for the nine-month period.
• As of September 30, 2024, the company had cash and cash equivalents of $13.52 million.
• The company's lead product candidate, elraglusib, is currently in Phase 2 clinical development.

Sentiment

Score: 4

Explanation: The document highlights the company's successful IPO and transition to a public company, but also emphasizes the significant financial challenges and risks associated with its early stage of development. The company's dependence on a single product candidate and its reliance on third parties for manufacturing and clinical trials are also concerning. The overall sentiment is cautiously negative due to the company's financial situation and the inherent risks of drug development.

Positives

• The successful completion of the IPO provides the company with significant capital to fund its operations.
• The conversion of preferred stock and convertible notes simplifies the company's capital structure.
• The company has a lead product candidate, elraglusib, in Phase 2 clinical development.

Negatives

• The company has incurred significant operating losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company is highly dependent on the success of elraglusib, its only product candidate.
• The company has a limited operating history and no products approved for commercial sale.
• The company relies on third parties for manufacturing and clinical trials.

Risks

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company is highly dependent on the success of elraglusib, its only product candidate.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or difficulties.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's stock price could be highly volatile.
• The company may not be able to obtain regulatory approval for elraglusib or any future product candidates.
• The company may not be able to commercialize elraglusib or any future product candidates successfully.
• The company may not be able to obtain adequate reimbursement for its products.
• The company may be subject to product liability claims.
• The company may be subject to intellectual property disputes.
• The company may be subject to cybersecurity incidents.
• The company may be subject to healthcare laws and regulations.
• The company may be subject to anti-corruption and anti-money laundering laws.
• The company may be subject to changes in tax law.
• The company may be subject to the penny stock rules.
• The company may be subject to the risk of a government shutdown.
• The company may be subject to the risk of a pandemic or epidemic disease outbreak.
• The company may be subject to the risk of a change in geopolitical relationships with China.
• The company may be subject to the risk of a change in the political and economic policies of the Chinese government.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Bayh-Dole Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding orphan drug designation.
• The company may be subject to the risk of a change in the U.S. government's policy regarding Fast Track designation.
• The company may be subject to the risk of a change in the U.S. government's policy regarding Breakthrough designation.
• The company may be subject to the risk of a change in the U.S. government's policy regarding PRIME designation.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Drug Price Competition and Patent Term Restoration Act of 1984.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Patient Protection and Affordable Care Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Inflation Reduction Act of 2022.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Medicare and Medicaid programs.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Physician Payments Sunshine Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Foreign Corrupt Practices Act of 1977.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the USA PATRIOT Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the U.S. Export Administration Regulations.
• The company may be subject to the risk of a change in the U.S. government's policy regarding U.S. Customs regulations.
• The company may be subject to the risk of a change in the U.S. government's policy regarding economic and trade sanctions regulations administered by the U.S. Treasury Departments Office of Foreign Assets Controls.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Sarbanes-Oxley Act of 2002.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Dodd-Frank Wall Street Reform and Consumer Protection Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the listing requirements of the Nasdaq Global Market.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Securities Act of 1933.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Securities Exchange Act of 1934.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Jumpstart Our Business Startups Act of 2012.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Black-Scholes valuation model.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the option pricing method (OPM).
• The company may be subject to the risk of a change in the U.S. government's policy regarding the hybrid method.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the probability-weighted expected return method (PWERM).
• The company may be subject to the risk of a change in the U.S. government's policy regarding the treasury stock method.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the if-converted method.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the two-class method.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Bayh-Dole Act of 1980.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Drug Price Competition and Patent Term Restoration Act of 1984.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Budget Control Act of 2011.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the American Taxpayer Relief Act of 2012.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the American Rescue Plan Act of 2021.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Inflation Reduction Act of 2022.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the U.S. Foreign Corrupt Practices Act of 1977.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the U.S. Travel Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the USA PATRIOT Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the U.S. Export Administration Regulations.
• The company may be subject to the risk of a change in the U.S. government's policy regarding U.S. Customs regulations.
• The company may be subject to the risk of a change in the U.S. government's policy regarding economic and trade sanctions regulations administered by the U.S. Treasury Departments Office of Foreign Assets Controls.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Sarbanes-Oxley Act of 2002.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Dodd-Frank Wall Street Reform and Consumer Protection Act.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the listing requirements of the Nasdaq Global Market.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Securities Act of 1933.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Securities Exchange Act of 1934.
• The company may be subject to the risk of a change in the U.S. government's policy regarding the Jumpstart Our Business Startups Act of 2012.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the foreseeable future as it continues the clinical development of, seeks regulatory approval for, and potentially commercializes elraglusib and potentially seeks to discover and develop additional product candidates.

Management Comments

• Management anticipates, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy the Companys operational and capital requirements through twelve months from the issuance date of these unaudited condensed consolidated financial statements.

Industry Context

The biopharmaceutical industry is highly competitive, and Actuate Therapeutics faces competition from other companies developing cancer therapies. The company's success will depend on its ability to successfully develop, obtain regulatory approval for, and commercialize elraglusib or any future product candidates.

Comparison to Industry Standards

• Actuate Therapeutics is a clinical-stage biopharmaceutical company, and its financial results are typical for companies at this stage of development.
• Many biopharmaceutical companies at this stage incur significant operating losses and rely on external funding to support their operations.
• The company's research and development expenses are consistent with industry standards for companies developing novel therapies.
• The company's general and administrative expenses are also consistent with industry standards for companies of its size and stage of development.
• The company's cash position is relatively strong following its IPO, but it will need to continue to raise capital to fund its operations.
• The company's reliance on third parties for manufacturing and clinical trials is also common in the biopharmaceutical industry.
• The company's dependence on a single product candidate, elraglusib, is a risk factor that is not uncommon in the biopharmaceutical industry, but it does make the company more vulnerable to setbacks in the development of that product candidate.
• The company's need to obtain regulatory approval for its product candidate is also a common risk factor in the biopharmaceutical industry.
• The company's need to obtain adequate reimbursement for its products is also a common risk factor in the biopharmaceutical industry.
• The company's need to protect its intellectual property is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with healthcare laws and regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with anti-corruption and anti-money laundering laws is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with data protection laws and regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with environmental, health and workplace safety laws and regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with export control and import laws and regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with economic and trade sanctions regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with tax laws is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the penny stock rules is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the listing requirements of the Nasdaq Global Market is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Securities Act of 1933 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Securities Exchange Act of 1934 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Jumpstart Our Business Startups Act of 2012 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Sarbanes-Oxley Act of 2002 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB) is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Black-Scholes valuation model is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the option pricing method (OPM) is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the hybrid method is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the probability-weighted expected return method (PWERM) is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the treasury stock method is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the if-converted method is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the two-class method is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Bayh-Dole Act of 1980 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Drug Price Competition and Patent Term Restoration Act of 1984 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Budget Control Act of 2011 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the American Taxpayer Relief Act of 2012 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the American Rescue Plan Act of 2021 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the Inflation Reduction Act of 2022 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the U.S. Foreign Corrupt Practices Act of 1977 is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the U.S. Travel Act is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the USA PATRIOT Act is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with the U.S. Export Administration Regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with U.S. Customs regulations is also a common risk factor in the biopharmaceutical industry.
• The company's need to comply with economic and trade sanctions regulations administered by the U.S. Treasury Departments Office of Foreign Assets Controls is also a common risk factor in the biopharmaceutical industry.

Related Party Transactions

• The Company issued convertible promissory notes to Bios Clinical Opportunity Fund, LP, a fund affiliated with a current member and a former member of the board of directors of the Company and a majority shareholder.
• The Company issued a promissory note to Bios Clinical Opportunity Fund, LP, a fund affiliated with a current member and a former member of the board of directors of the Company and a majority shareholder.
• The Company incurred expenses for services provided by Pacific BioPharma Logistics, Inc., where a Vice President of Manufacturing for the Company is an unpaid advisor and his spouse is a shareholder.

Stakeholder Impact

• Shareholders will experience dilution as a result of future sales or issuances of common stock.
• Employees may be affected by changes in the company's operations or financial condition.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors may be affected by the company's financial condition.

Next Steps

• The company will continue to advance the clinical development of elraglusib.
• The company will seek additional financing to support its operations.
• The company will continue to evaluate potential acquisitions and/or licenses of patents, compounds, and technologies.

Key Dates

Keywords

elraglusib, clinical trials, biopharmaceutical, cancer, IPO, Nasdaq, research and development, regulatory approval, financial results, pharmaceutical